STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
STAT3 signaling plays the pivotal role in tumorigenesis through EZH2 epigenetic modification, which enhanced STAT3 activity by increased tyrosine phosphorylation of STAT3. Here, another possible feedback mechanism and clinical significance of EZH2 and STAT3 were investigated in gastric cancer (GC). STAT3, p-STAT3 (Tyr 705) and EZH2 expression were examined in 63 GC specimens with matched normal tissues by IHC staining. EZH2 and STAT3 were also identified in five GC cell lines using RT-PCR and western blot analyses. p-STAT3 protein was detected by western blotting. In order to investigate whether EZH2 expression was directly regulated by STAT3, EZH2 expression was further detected using siRNA for STAT3 or IL-6 stimulation, with dual luciferase reporter analyses, electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assays. The clinical significance of STAT3, p-STAT3 and EZH2 expression was evaluated by multi-factor COX regression and Kaplan-Meier analyses. Hyper-activation of STAT3, p-STAT3 and EZH2 expression were observed in GC cells and tissues. STAT3 signaling was correlated with EZH2 expression in GC ( R = 0.373, P = 0.003), which was consistent with our data showing that STAT3 as the transcriptional factor enhanced EZH2 transcriptional activity by binding the relative promoter region (-214 ~ -206). STAT3 was an independent signature for poor survival ( P = 0.002). Patients with STAT3 + /EZH2 + or p-STAT3 + /EZH2 + had a worse outcome than others ( P < 0.001); Besides, high levels of STAT3 and EZH2 was associated with advanced TNM staging ( P = 0.017). Moreover, treatment with a combination of siSTAT3 and EZH2-specific inhibitor, 3-deazaneplanocin A (DZNEP), increased the apoptotic ratio of cells. It is benefit for targeting STAT3-EZH2 interplay in GC treatment. Our results indicate that STAT3 status mediated EZH2 upregulation, associated with advanced TNM stage and poor prognosis, suggesting that combination with knockdown of STAT3 and EZH2 inhibitor might be a novel therapy in GC treatment. Collectively, STAT3, p-STAT3 and EZH2 expression were provided for the precision medicine in GC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 1×
“Aberrant IL-6/STAT3 signaling in cancer cells have emerged as a major mechanism for cancer initiation and development [10, 11].”
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“Aberrant IL-6/STAT3 signaling in cancer cells have emerged as a major mechanism for cancer initiation and development [10, 11].”
The Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204
Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development · doi:10.1101/gad.1524107 · Cited by 895
Li, Y., de Haar, C., Chen, M., Deuring, J., Gerrits, M. M., Smits, R., Xia, B., Kuipers, E. J., & van der Woude, C. J. (2010) · Gut · doi:10.1136/gut.2009.184176 · Cited by 339 · cited 1×
“Upon activation, it is mostly involved in carcinogenesis [13, 14].”
Rush, M., Appanah, R., Lee, S., Lam, L. L., Goyal, P., & Lorincz, M. C. (2009) · Epigenetics · doi:10.4161/epi.4.6.9392 · Cited by 83
Cited by
Signaling pathways and therapeutic interventions in gastric cancer
Lei, Z.-N., Teng, Q.-X., Tian, Q., Chen, W., Xie, Y., Wu, K., Zeng, Q., Zeng, L., Pan, Y., Chen, Z.-S., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01190-w · Cited by 322
Self-citationSTAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner
Sun, S., Wu, Y., Guo, W., Yu, F., Kong, L., Ren, Y., Wang, Y., Yao, X., Jing, C., Zhang, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2248 · Cited by 93
Self-citationGuan, X., Yang, J., Wang, W., Zhao, B., Hu, S., Yu, D., Yuan, L., Shi, Y., Xu, J., Dong, J., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106703 · Cited by 33
Self-citation
Metadata
- Authors
- Pan, Y.-M., Wang, C.-G., Zhu, M., Xing, R., Cui, J.-T., Li, W.-M., Yu, D.-D., Wang, S.-B., Zhu, W., Ye, Y.-J., Wu, Y., Wang, S., & Lu, Y.-Y.
- Venue
- Molecular Cancer
- Published
- 2016-12
- Volume
- 15
- Issue
- 1
- Pages
- 79-79
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2559891252
- Cited by
- 183
- References
- 7
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer. https://app.cochat.ai/papers/10.1186/s12943-016-0561-z
- The paper
- Pan, Y.-M., Wang, C.-G., Zhu, M., Xing, R., Cui, J.-T., Li, W.-M., Yu, D.-D., Wang, S.-B., Zhu, W., Ye, Y.-J., Wu, Y., Wang, S., & Lu, Y.-Y. (2016). STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer. Molecular Cancer. https://doi.org/10.1186/s12943-016-0561-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.